European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Israel - English - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone - foster 200/6 is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - betamethasone; fusidic acid - cream - 20 mg/g+ 1 milligram(s)/gram - corticosteroids, potent, combinations with antibiotics; betamethasone and antibiotics

Ireland - English - HPRA (Health Products Regulatory Authority)

sofibel - hydrocortisone acetate; benzyl benzoate; bismuth subgallate; bismuth oxide; balsam peru; zinc oxide - ointment - 0.25/1.25/2.25/0.875/1.875/10.75 gram/100gram - corticosteroids, weak, combinations with antiseptics

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - betamethasone; clioquinol - cream - 0.1 %w/w + 3.0 percent weight/weight - corticosteroids, potent, combinations with antiseptics; betamethasone and antiseptics

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - betamethasone dipropionate, clotrimazole - cream - 0.064/1.0 - corticosteroids, potent, combinations with antibiotics

Israel - English - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; clotrimazole; gentamicin (as sulfate) - cream - clotrimazole 10 mg/g; betamethasone as dipropionate 0.5 mg/g; gentamicin (as sulfate) 1 mg/g - corticosteroids, potent, other combinations - treatment of corticosteroid-responsive dermatoses when complicated by infections caused by bacteria (sensitive to gentamicin) and fungi (sensitive to clotrimazole) or when the possibility of such infections is suspected. the cream is suitable for the use of oozing eczema.

European Union - English - EMA (European Medicines Agency)

intervet international bv - resocortol butyrate - corticosteroids, dermatological preparations - dogs - treatment of acute localised moist dermatitis.

European Union - English - EMA (European Medicines Agency)

theravia - dexamethasone - multiple myeloma - corticosteroids for systemic use - treatment of multiple myeloma.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol propionate - solution - external - clobetasol propionate 0.05 %w/w - clobetasol - clobetasol - for the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.